Composition for preventing improving or treating degenerative brain diseases comprising mixture of Glycyrrhiza cultivar Sorgum bicolor L. Moench and Bombyx mori L

• Main Authors: JANG GWI YEONG, CHOI JEHUN, KIM HYUNG DON, KIM DONG HWI, KWEON HAE YONG, CHOI SU JI, PARK SAET BYUL, LEE SEUNG EUN, LEE JEONG HOON
• Format: Patent
• Language: English; Korean
• Published: 16.12.2022
• Subjects: FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The present invention relates to a composition for preventing, improving, or treating degenerative brain diseases, comprising Glycyrrhiza uralensis, Sorgum bicolor (L.) moench, and pupae of Bombyx mori L as an active ingredient. It has been confirmed that, in vitro, complex extracts of pupae of Bombyx mori L, Glycyrrhiza uralensis, and Sorgum bicolor (L.) moench show effects of inhibiting acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), reducing cytotoxicity, inhibiting nitric oxide (NO) production, and inhibiting beta-amyloid toxicity. In addition, it has been confirmed that, in vivo, the Y-maze behavioral test results are excellent, and expression of BDNF and ERK 1/2 in brain hippocampus and expression of choline acetyltransferase (ChAT) are excellent, so as to be used as a therapeutic agent and food composition for degenerative brain diseases. 본 발명은 감초, 수수 및 누에나방의 번데기 혼합물을 유효성분으로 포함하는 퇴행성 뇌질환 예방, 개선 또는 치료용 조성물의 관한 것으로, 누에나방의 번데기, 감초 및 수수의 복합 추출물은 in vitro 상에서, 아세틸콜린에스테라제(AChE) 및 부티릴콜린에스테라제(BuChE) 억제, 세포독성 감소, 산화질소(NO) 생성 억제, 베타아밀로이드 독성 억제 효과가 나타남을 확인하였다. 또한, in vivo 상에서, Y-maze 행동시험 결과가 우수하고, 뇌 해마조직의 BDNF 및 ERK 1/2 발현, 콜린아세틸트랜스퍼라제(ChAT) 발현이 우수함을 확인하여, 퇴행성 뇌질환 치료제 및 식품 조성물로 이용될 수 있다.